The revolutionary discovery in 1991 by Soltis and Cassis that perivascular adipose tissue (PVAT) has an anti-contractile effect changed how we think about the vasculature. Most experiments on vascular pharmacology begin by removing the fat surrounding vessels. Thus, PVAT was thought to have a minor role in vascular function and its presence was just for structural support. The need to rethink PVAT's role was precipitated by observations that obesity carries a high cardiovascular risk and PVAT dysfunction is associated with obesity. PVAT is a vascular-adipose organ that has intimate connections with the nervous and immune system. A complex world of physiology resides in PVAT, including the presence of an 'adrenergic system' that is able to release, take up and metabolize noradrenaline. Adipocytes, stromal vascular cells and nerves within PVAT contain components that make up this adrenergic system. Some of the great strides in PVAT research came from studying adipose tissue as a whole. Adipose tissue has many roles and participates in regulating energy balance, energy stores, inflammation and thermoregulation. However, PVAT is dissimilar from non-PVAT adipose tissues. PVAT is intimately connected with the vasculature, which is what makes its role in body homeostasis unique. The adrenergic system within PVAT may be an integral link connecting the effects of obesity with the vascular dysfunction observed in obesity-associated hypertension, a condition in which the sympathetic nervous system has a significant role. This review will explore what is known about the adrenergic system in adipose tissue and PVAT, plus the translational importance of these findings.
Introduction
Perivascular adipose tissue (PVAT) surrounds blood vessels and represents the fourth layer of the blood vessel, the 'tunica adiposa' (Chaldakov et al., 2012) . The morphology of the adipocytes, inflammatory response and level of differentiation in PVAT differs from those in non-PVAT depots (Guzik et al., 2007; Rittig et al., 2012) . Moreover, the location of the adipocytes found in PVAT differ. For example, PVAT around branches of the superior mesenteric artery (SMA) and mesenteric artery (MA) in rats consists of unilocular adipocytes typically found in white adipose tissue (WAT), while aortic PVAT is a mixed PVAT with brown adipose tissue (BAT)-like adipocytes (Gao, 2007) . The expression of genes (including high levels of Ucp-1) and the phenotype of adipocytes (multilocular mitochondria-rich adipocytes) of mouse thoracic aortic PVAT have been shown to be similar to interscapular BAT (IBAT) (Fitzgibbons et al., 2011) . Non-PVAT WAT depots have been intensely studied and include the gonadal (epididymal and periovarian), retroperitoneal, perirenal and subcutaneous WAT (Cinti, 2009) . IBAT is the most commonly studied BAT depot. Research on non-PVAT depots has been informative and serves as a starting point to understanding PVAT. This review will discuss non-PVAT adipose tissue as a surrogate for PVAT when information on the adrenergic system in PVAT specifically is not available. Judging from the uniqueness of PVAT, we expect that what we already know about fat tells part -but not all -of the story of PVAT.
As we discover the functions of PVAT that go beyond structural support and affect vascular homeostasis (including functions that affect the proliferation, differentiation, inflammation and contractility of the vasculature as reviewed by Szasz and Webb, 2012) , a neuro-immune-adipose 'triactome' was identified that connects adipose tissue, nerves and the immune system to the vasculature in a dynamic physiological system (Chaldakov et al., 2014) . Adipose tissue is innervated by sensory nerves (Bartness and Song, 2007) but, as yet, no studies have been done to locate sensory nerves in PVAT. Furthermore, although scant evidence exists for the parasympathetic innervation of adipose tissue (Fliers et al., 2003; Giordano et al., 2006) , this has not been studied in PVAT. Thus, these two nervous systems will not be reviewed here. However, there is substantial evidence indicating sympathetic innervation of adipose tissue and PVAT. Adipose tissue and PVAT contain noradrenaline (NA); the amount of NA present in adipose tissue depends on its location. NA has been shown to be present in the aortic PVAT and SMA PVAT of male Sprague-Dawley rats. By comparison, retroperitoneal WAT has far less NA than PVAT (Ayala-Lopez 
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These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015 /16 ( a,b,c,d,e Alexander et al., 2015a ,b,c,d,e). et al., 2014 . In contrast, the levels of adrenaline in aortic PVAT, the brown fat pad, SMA PVAT and retroperitoneal adipose tissue have been found to be low to non-detectable (Ayala-Lopez et al., 2014) . Hence, as appreciable amounts of adrenaline have not been found in adipose tissue or in PVAT, we have not included adrenaline in this review. Thus, in this review the adrenergic components we describe are those that can release, take up and metabolize NA within PVAT ( Figure 1 ) and we have focused on the evidence for this system's effects on blood vessel function.
Sympathetic nervous system innervation in adipose tissue
Studies by Diculescu and Stoica (1970) carefully investigated the adrenergic innervation in WAT, including fluorochemical staining of adrenergic nerves within rat peri-epididymal WAT and WAT of the mesentery. The nerves were observed to innervate individual adipocytes, and mast cells were frequently located along the nerve fibres. The authors also noted that BAT contained more sympathetic nerve fibres than WAT (Diculescu and Stoica, 1970) . Nerves innervating WAT originate from areas of the CNS that are associated with the regulation of energy balance, specifically the brainstem and forebrain (Shi and Bartness, 2001 ). Contreras et al. (2014) demonstrated the importance of sympathetic activation for the maintenance of a brown adipocyte phenotype. Genetic tagging of adipocytes by adiponectinCreER assisted in the conclusion that brown adipocytes exist in inguinal adipose tissue from young mice but then turn into white adipocytes without continuous sympathetic stimulation (Contreras et al., 2014) . Thus, sympathetic innervation is necessary not only for lipolysis but also for maintaining the thermogenic capacity of brown adipocytes, and nerve density may affect this. Support for the conclusion that nerve density is important for conferring a brown adipocyte phenotype is provided by the observation that the density of adrenergic nerve fibres [as measured by tyrosine hydroxylase (TH) immunohistochemical staining] correlated with the proportion of brown adipocytes in visceral and subcutaneous WAT from female mice (Murano et al., 2009) . Stimulation of sympathetic activity with a 10 day period of cold-acclimatization increased the amount of TH-positive nerve fibres in these tissues (Murano et al., 2009) . This suggests that sympathetic stimulation to WAT is less active than that of BAT. Thus, brown-like PVAT depots may be innervated more densely than WAT-like PVAT depots. The differences in sympathetic innervation and release of NA between specific PVAT depots remain to be studied.
Sympathetic nervous system in PVAT
Immunochemical analysis by Ballard et al. (1974) of adipose tissue surrounding canine mesenteric arteries revealed a pool of adipocytes in contact with nerves and another group of adipocytes that were not in contact with nerves. Later, Slavin and Ballard (1978) , by careful examination of Sprague-Dawley rat mesenteric adipose tissue by glyoxylic Figure 1 Diagram of the adrenergic system in PVAT. Adipocytes, lymphocytes, macrophages, mast cells and nerves comprise the adrenergic system within PVAT. AAD, amino acid decarboxylase; DβH, dopamine β-hydroxylase; DA, dopamine; DOPA, 3,4-dihydroxyphenylalanine; TH, tyrosine hydroxylase.
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N Ayala-Lopez and S W Watts acid/sodium molybdate staining and electron microscopy, found that only 2-3% of all adipocytes were directly connected to adrenergic nerves. Some of the nerves visualized adjacent to adipocytes contained synaptic vesicles. As NA has a low affinity for the β 3 -adrenoceptor (Lafontan et al., 1995) , high concentrations of NA at the nerve-adipocyte junction would be necessary in order to activate lipolysis. Unfortunately, whether PVAT adipocytes specifically are directly in contact with nerves through varicosities has not been investigated. Focusing on PVAT, Bulloch and Daly (2014) published images of mouse mesenteric artery PVAT stained for the pan-neuronal marker PGP 9.5, which illuminated nerve fibres (all types) that traversed through PVAT. Glyoxylic acid staining for catecholamines in male rat mesenteric resistance artery PVAT revealed diffuse staining in this PVAT depot, suggesting the wide-spread presence of catecholamines in PVAT (Ayala-Lopez et al., 2014) . Differences in these findings may reflect the possibility that areas within the same adipose depot vary with regard to density of innervation. Characterization of the innervation of each PVAT depot and of individual adipocytes is needed to elucidate its contribution to the adrenergic system in each tissue.
Catecholamine release and synthesis by adipose tissue
Sympathetic nerves are spread throughout adipose tissue, at times directly innervating adipocytes and at other times passing through adipose tissue to innervate the arteries. Neuronal release of NA and the release of NA from other cell types in adipose tissue have been explored by several groups.
The sympathomimetic tyramine has been shown to stimulate the release of catecholamines from PVAT indicating that NA is probably stored within PVAT (Ayala-Lopez et al., 2014) . Aortic PVAT from male rats exposed to tyramine released NA (NA content was measured by HPLC). PVAT around the SMA also released NA in response to tyramine, but the amount released was less than aortic PVAT. The tyramine-dependent release of catecholamines in the rat aorta was reduced by inhibiting transporters of NA with nisoxetine and inhibiting the vesicular monoamine transporter 2 with tetrabenazine. To determine whether these released catecholamines could influence arterial contraction, vessels with and without PVAT were mounted in isolated tissue baths for measurement of isometric contraction and exposed to increasing concentrations of tyramine. The aorta with PVAT contracted to tyramine in a concentration-dependent manner, but this effect was not observed when the PVAT had been removed. Furthermore, removal of PVAT reduced the contraction of the SMA to electrical field stimulation (EFS), a process mediated by sympathetic nerves as it was abolished by tetrodotoxin or prazosin (Ayala-Lopez et al., 2014) . Surgical removal of the coeliac ganglion (the source of neural adrenergic innervation to the mesentery) did not reduce the tyramine-induced contraction of the SMA with PVAT, supporting the existence of functional catecholamines within PVAT that are independent of nerves (Ayala-Lopez et al., 2014) . The level of innervation of the mesenteric arteries and the aorta is different. It should also be noted that while the aorta is sparsely innervated, the vasa vasorum has been reported to have dense sympathetic innervation in rabbit aortas (Kienecker and Knoche, 1978) . Soltis and Cassis (1991) demonstrated that PVAT was necessary for EFS to contract the aorta, and this effect was reduced by the angiotensin II receptor inhibitor 1-sarcosine-8-isoleucine angiotensin II (Sar 1 , Ile 8 -AII), indicating that the EFS-stimulated contraction is in part angiotensin II-dependent. Thus, PVAT contains a mechanism of storage and release of catecholamines, which could in part be nerveindependent and involve angiotensin II. If catecholamine release can occur independently from nerve stimulation, where does the NA come from? The idea that the adipocyte could contain a system for the handling of vasoactive amines was first presented by Stunes et al. (2011) . A biochemical pathway for the synthesis and reuptake of 5-HT was identified in cultures of primary rat adipocytes isolated from visceral abdominal adipose tissue; the culture supernatants were found to contain 5-HT and the adipocytes expressed mRNA for 5-HT 2A , 5-HT 2B and 5-HT 2C receptors, tryptophan hydroxylase 1 (Tph1) and the 5-HT transporter (SERT; Stunes et al., 2011) . Interestingly, sympathetic denervation of SMA PVAT reduced NA content only modestly (Ayala-Lopez et al., 2014) , an observation that supports recent studies implicating adipocytes in the synthesis of catecholamines (Vargovic et al., 2011 Kvetnansky et al., 2012) . Thus, a role for the adipocyte in the production of NA in PVAT may exist.
Other cells in PVAT include those of the stromal vascular fraction (SVF) such as macrophages (Brown et al., 2003) and lymphocytes (Josefsson et al., 1996; Qiu et al., 2004) . Dopamine and NA are synthesized in lymphocytes and have a role in inducing apoptotic signals (Josefsson et al., 1996) . Furthermore, splenic B and T lymphocytes from mice express mRNA for TH and phenylethanolamine N-methyltransferase (PNMT), and the splenocytes increase their expression of these substances in response to stress by immobilization . The role of catecholamines produced in lymphocytes present in PVAT and their targets has not been studied. The secretion of catecholamines by macrophages present in adipose tissue may play a role in adaptive thermogenesis and stimulating lipolysis (Nguyen et al., 2011) . Peritoneal macrophages, activated by an injection of IL-4 to male mice, have an increased expression of the catecholamine synthesizing enzymes TH, dopa decarboxylase and dopamine β-hydroxylase. Furthermore, IL-4 increases the NA content in WAT of the mice, indicating that the activation of macrophages may stimulate NA production within adipose tissue (Nguyen et al., 2011) .
The finding that macrophages can be active secretors of catecholamines is important as macrophage infiltration of tissues commonly occurs in obesity (Weisberg et al., 2003) . Superoxide generated from infiltrating macrophages disrupts normal pre-synaptic α 2 -adrenoceptor function, increasing the release of NA from the nerves, a mechanism that elevates blood pressure (Thang et al., 2015) . Thus, macrophage infiltration in PVAT may influence NA release and blood pressure in disease.
NA released from either neuronal or non-neuronal sources in PVAT can have effects other than directly stimulating vasoconstriction through binding of adrenoceptors on vascular smooth muscle cells. For example, NA-induced mitochondrial superoxide (O 2 À ) production and its rapid dismutation of superoxide into H 2 O 2 by manganese-superoxide dismutase in the thoracic aorta are a mechanism by which PVAT exhibits an anti-contractile effect (Costa et al., 2016) . Thus, NA released within PVAT may increase vascular tone through direct action on α adrenoceptors on vascular smooth muscle or could tip the balance towards relaxation by stimulating H 2 O 2 production.
Catecholamine uptake by PVAT and adipose tissue
Inactivation of catecholamines within an adrenergic system occurs through uptake and metabolism. Adipocytes have a functional uptake system for NA first described by Pizzinat et al. (1999) ; they identified the uptake of [ 3 H]-NA into adipocytes isolated from adipose tissue from women that had undergone abdominal or mammary dermolipectomies. There is also evidence supporting catecholamine uptake by PVAT specifically. In the rat thoracic aorta, the presence of PVAT shifts the NA concentration-contractile response curve to the right compared to that in aortas with the PVAT removed. Incubation with the uptake-1 and uptake-2 transporter inhibitors deoxycorticosterone and desipramine removes this effect of PVAT on the response to NA (Soltis and Cassis, 1991) . The uptake-1 and uptake-2 transporter are now known as the noradrenaline transporter (NET) and organic cation transporter 3 (OCT3) respectively. The fluorescent dye 4-(À4-(dimethylamino)-styryl)-Nmethylpyridinium (ASP + ), a substrate for NA transporters, was used to probe the existence of a NA transport system in mesenteric resistance artery PVAT from male rats. Images of ASP + staining by confocal microscopy showed that mesenteric resistance artery PVAT adipocytes internalize ASP + .
Functional studies of NA uptake into mesenteric resistance artery PVAT revealed that NA was internalized in a manner that was sensitive to inhibition by transporter inhibitors desipramine with corticosterone or citalopram with corticosterone. NA uptake into thoracic aorta PVAT was sensitive to inhibition by the OCT3 inhibitor corticosterone. Immunohistochemistry and PCR have been used to demonstrate that OCT3 is abundant in PVAT adipocytes around the mesenteric resistance arteries and in aortic PVAT (Ayala-Lopez et al., 2015) . The gene for OCT3 (Slc22a3) is highly expressed in adipose tissue but less so in the other tissues examined (Jacobsson et al., 2007) . PVAT may act as a NA sink to remove NA from the adventitial side of the blood vessel with the effect of reducing vascular contraction. The uptake of NA has also been examined in IBAT where it was found to be mediated by NET (King et al., 1999) . This is in contrast to mesenteric resistance artery PVAT, where the expression and activity of NET are low, and the transporter responsible for the uptake of NA is OCT3, present in adipocytes (Ayala-Lopez et al., 2015) . In IBAT, angiotensin II stimulates NA uptake, as demonstrated by the increase in [ 3 H]-nisoxetine binding after an infusion of angiotensin II to rats (King et al., 2013) . Whether angiotensin II would also stimulate NA uptake through OCT3 has yet to be determined.
The uptake system involved in PVAT-mediated regulation of arterial tone may be an agonist (NA) specific system. This one mechanism that could contribute to PVAT's anticontractile effect in addition to the other known mechanisms, such as the release of relaxant factor(s) that reduce contraction of the rat aorta to phenylephrine and angiotensin II (Löhn et al., 2002) and the activation of vascular smooth muscle potassium channels (Lynch et al., 2013; Weston et al., 2013) .
Catecholamine metabolism by PVAT and adipose tissue Pizzinat et al. (1999) were the first to identify an active system of uptake and metabolism for amines in white adipose tissue. They demonstrated that human mammary adipose tissue adipocytes express both MAO-A and MAO-B, with MAO-A being the more active enzyme. Since MAO-A is located intracellularly, amines would have to enter the cell first before being metabolized. The authors demonstrated that NA uptake occurred through the extraneuronal transporter (now known as OCT3; Pizzinat et al., 1999) , a finding further supported by functional studies showing that NA uptake in rat mesenteric resistance artery PVAT is also mediated by OCT3 (Ayala-Lopez et al., 2015) .
The semicarbazide sensitive amine oxidase (SSAO) has high activity in adipose tissue and thus must be considered as a potential amine metabolizer in PVAT. SSAO is involved in adipogenesis (Mercier et al., 2001) , cell differentiation (Filip et al., 2016) and glucose transport (El Hadri et al., 2002) . Elliott et al. (1989a) investigated amine metabolism in rat isolated mesenteric arteries and found that metabolism of the substrates tyramine and benzylamine was carried out by SSAO and to a lesser extent MAO-A. Inhibition of both MAO-A and SSAO (with clorgyline and MDL 72145, respectively) was required to affect contraction of the arteries to tyramine (Elliott et al., 1989b) . Studies to assess this effect in arteries with PVAT are needed in addition to studies investigating whether NA is metabolized by SSAO in PVAT.
Macrophages are another cell type in PVAT that can metabolize NA (Chaitidis et al., 2005) . The metabolizing enzyme COMT has been found in dental pulp macrophages (Inoue et al., 1991) . Rat peritoneal macrophages were found by Vega et al. (2004) to contain SSAO. However, the presence of COMT or SSAO in adipose tissue macrophages has not yet been reported. In vitro experiments using U937 cells and human peripheral blood macrophages revealed that alternatively activated macrophages express MAO-A (Chaitidis et al., 2005; Bhattacharjee et al., 2013) . This, paired with the knowledge that PVAT is pro-inflammatory in nature compared with other types of fats (Chatterjee et al., 2009) , further supports the notion that metabolism is involved in the inactivation of NA in PVAT. Thus, the mechanisms of PVAT NA metabolism and their effect on blood vessel contraction to NA are important to understand.
Adipocyte-secreted factors that have an effect on the adrenergic system Adipose tissue can interact with the adrenergic system through the release of various adipokines. Three important adipokines that have adrenergic actions are leptin, resistin BJP N Ayala-Lopez and S W Watts and angiotensin II, all of which are clinically important in hypertension and obesity.
Notably, leptin is secreted from adipocytes and is part of a leptin-sympathetic nervous system (SNS) feedback loop involved in controlling energy balance (Rayner and Trayhurn, 2001) . Circulating leptin levels correlate with fat mass (Rayner and Trayhurn, 2001) , are increased in obesity (Considine et al., 1996; Couillard et al., 1997) and higher in rodents fed a high fat diet (HFD) compared with those on a normal diet (Marques et al., 2015; Bussey et al., 2016) . Evidence for the leptin-SNS feedback loop is supported by a study that found that female C57BL/6J ob/ob mice administered leptin have increased sympathetic activity to the IBAT as measured by noradrenaline turnover (NETO; Collins et al., 1996) . Also, male rats that were administered leptin i.v. over 3 h had increased sympathetic nerve activity in their BAT compared with rats administered vehicle (Haynes et al., 1997) . Although SNS activity was increased, arterial pressure and heart rate were not. However, increases in arterial pressure and heart rate were observed in a study where leptin was administered chronically to male Sprague-Dawley rats (Shek et al., 1998 ). Leptin's ability to increase sympathetic activity is leptin receptor-dependent as leptin did not increase sympathetic activity when administered to Zucker fa/fa obese rats that have a mutated leptin receptor (Haynes et al., 1997 ). Leptin's ability to increase sympathetic activity is mediated through central mechanisms. Administration of leptin centrally by an i.c.v. injection to rhesus macaques increased circulating NA (Tang-Christensen et al., 1999). Interestingly, NA can also inhibit leptin release, suggesting a leptin-SNS feedback loop. Addition of NA or the β 3 -adrenoceptor agonist CL316,243 reduced the amount of leptin released in rat epididymal WAT adipocytes (Gettys et al., 1996) . However, inhibiting catecholamine synthesis, by an i.p. injection of α-methyl-p-tyrosine, increased circulating leptin levels and leptin gene expression in the epididymal WAT of male mice (Rayner et al., 1998) . In contrast, Evans et al. (1999) found that depletion of catecholamines by reserpine increased Ob mRNA expression in BAT, but not WAT, of male mice. Exposure to cold reduced leptin expression in fat by a mechanism that was inhibited by propranolol (β 1 -and β 2 -adrenoceptor blocker) and SR 59230A (β 3 -adrenoceptor antagonist; Evans et al., 1999) , indicating that sympathetic stimulation of β-adrenoceptors is necessary for stimulating leptin production.
PVAT's production of leptin was reduced in the aortic PVAT of spontaneously hypertensive rats compared with their normotensive controls (Galvez-Prieto et al., 2012) . In contrast, in the Dahl salt-sensitive (Dahl SS) rat, the aortic PVAT has a higher leptin content than the aortic PVAT of SS.13 BN rats (normotensive, non-salt hypersensitive control for the Dahl SS rat) (Spradley et al., 2016) . In high fat (HF) fed obese mice, aortic PVAT expression of leptin was markedly higher than that of lean mice (Ketonen et al., 2010) . Further investigations into the changes in leptin levels in different rodent models could be especially enlightening when considering obesity and hypertensive status. Resistin is released by white adipocytes, and circulating levels are increased in HF fed, ob/ob and db/db mice (Steppan et al., 2001) . Patients with essential hypertension have resistin levels that are positively associated with inflammatory status and endothelial dysfunction (Fang et al., 2013) .
Resistin inhibits dopamine and NA release in hypothalamic synaptosomes in vitro (Brunetti et al., 2004) . In a study of 302 adolescents by Souki et al. (2016) , serum resistin concentrations in males were increased with obesity, and non-obese females had higher levels of circulating resistin than males. However, obese females did not have higher resistin levels than non-obese females (Souki et al., 2016) . Circulating adiponectin, another adipocyte-derived factor, is decreased in obesity (Weyer et al., 2001 ). Adiponectin did not affect NA release in hypothalamic synaptosomes (Brunetti et al., 2004) . Thus, resistin but not adiponectin may play a role in hypothalamic control of energy balance through the release of NA.
Angiotensin II from PVAT affects arterial contraction by interacting with the adrenergic system. Soltis and Cassis (1991) found that contractions of the aorta to EFS were reduced in the presence of the α-adrenoceptor antagonist phentolamine and by incubating the tissue with the angiotensin II receptor inhibitor Sar 1 , Ile 8 -AII. Their findings suggest that endogenous angiotensin II within the PVAT potentiates the electrically-induced response. The mechanisms by which angiotensin II potentiates contractions to EFS were further explored by Lu et al. (2010) using male Wistar rats. The authors found that PVAT around mesenteric arteries expressed angiotensinogen, angiotensin converting enzyme (ACE) and angiotensin II. Inhibition of ACE by enalaprilat or inhibition of the angiotensin II receptor by candesartan reduced PVAT-dependent EFS-induced contractions of the SMA and in vivo administration of the ACE inhibitor quinapril lowered blood pressure (Lu et al., 2010) . Connecting the dots, Lu et al. (2010) proposed that these findings fit in with earlier studies that demonstrated that PVAT potentiates EFSinduced contractions possibly through the production of superoxide, a promoter of contraction, through activation of the MAPK/ERK pathway (Gao et al., 2006; Lu et al., 2010) and proposed that PVAT-derived angiotensin II was thus potentiating EFS-induced contractions through activation of MAPK/ERK. However, this hypothesis was not tested directly. Detection of a reduction in superoxide production or MAPK/ERK activation in response to EFS after inhibition of angiotensin II production would provide additional support for this hypothesis. Interestingly, experiments performed by Costa et al. (2016) in a different vessel, the aorta with PVAT, found that superoxide promoted relaxation due to its rapid dismutation to H 2 O 2 . Another mechanism that could explain how angiotensin II could potentiate EFS-induced contractions is through the activation of prejunctional angiotensin receptors to release NA (Cox et al., 1999) , and this remains to be examined in PVAT.
Beyond its ability to potentiate EFS-induced contractions, angiotensin II increases NA synthesis and uptake. King et al. demonstrated that angiotensin II facilitates neurotransmission to adipose tissue, which leads to a decrease in body weight (King et al., 2013) . Infusion of angiotensin II to rats increased the amount of [ 3 H]-nisoxetine binding in IBAT suggesting an increased uptake of NA (King et al., 2013) . NETO, as a measure of sympathetic activity, was increased during angiotensin II infusion in IBAT, epididymal fat, the left ventricle of the heart and the kidney (King et al., 2013) . Increased circulating levels of angiotensin II are observed in obese individuals after stimulation of β-adrenoceptors with isoprenaline (Goossens et al., 2007) . Taken together, these findings indicate angiotensin II in PVAT may affect on vascular function by potentiating sympathetically-induced contractions.
Adrenoceptors in adipose tissue
Several effects of NA on components of adipose tissue are mediated through activation of adrenoceptors and α 1 , α 2 , β 1 , β 2 and β 3 -adrenoceptors are found on adipocytes (Lafontan and Berlan, 1993) . The presence and distribution of adrenoceptors differ depending on the type of adipocyte and the adipose tissue depot. In white adipocytes, β adrenoceptor agonists stimulate lipolysis (β 1 , β 2 , β 3 ; which are Gs-coupled), glycogenolysis (β 1 ) and inhibit glucose transport (β 2 ; Lafontan and Berlan, 1993) . The α 1 -adrenoceptors are coupled to Gq and result in the activation of PKC and thermogenesis in brown adipocytes and glycogenolysis in white adipocytes (Lafontan and Berlan, 1993) . Stimulation of α 2 -adrenoceptors (Gi-coupled) results in adenylate cyclase inhibition, which results in a decrease in cAMP followed by a decrease in lipolysis (Lafontan and Berlan, 1993) . Beyond activation of lipolysis through adrenoceptors, NA can induce the release of fatty acids, which can activate thermogenesis, through direct activation of the uncoupling protein-1 in brown adipocytes; this was demonstrated in adipocytes isolated from female mice (Matthias et al., 2000) . Both α and β adrenoceptors have been shown to be present in PVAT; Bulloch and Daly (2014) stained mouse mesenteric artery PVAT with fluorescent ligands to α and β adrenoceptors and found binding for both. However, classification of the receptor subtypes in PVAT was not performed.
Mast cells have been demonstrated to have adrenoceptors, and these cells are found in PVAT along with adrenergic fibres (Diculescu and Stoica, 1970) . In vitro stimulation of β 2 -adrenoceptors in human mast cells with adrenaline enhanced their production of the pro-inflammatory cytokines IL-6, IL-8 and IL-13 in response to IL-1ß (Chi et al., 2004) .
Lymphocytes are another cell type found in PVAT that can be acted upon by NA. Stimulation of β 2 -adrenoceptors on mice splenic lymphocytes by NA inhibits TNF-α production (Vida et al., 2011) . Also α 1 -and α 2 -adrenoceptors have been shown to be expressed on T lymphocytes from rat mesenteric lymph nodes (Bao et al., 2007) . The addition of NA to splenocyte cultures or the stimulation of NA production by lymphocytes themselves following stress immobilization induces apoptosis (Josefsson et al., 1996; Laukova et al., 2013) . However, the effects of NA in adipose tissue lymphocytes have not been examined.
In addition to adipocytes, macrophages are one of most prevalent cell types in PVAT. Several groups have identified adrenoceptors in macrophages; β and α 2 -adrenoceptors are present in rat peritoneal macrophages (Abrass et al., 1985; Spengler et al., 1990) . Chi et al. (2003) found that macrophages can be stimulated by catecholamines to release NO; cultured RAW264.7 macrophages were treated with LPS in the presence of either adrenaline, NA or dopamine. LPS enhanced NO production by the macrophages, and interestingly, adrenaline and NA further enhanced this NO production and increased the expression of iNOS (Chi et al., 2003) .
The implication is that catecholamine-dependent increases in NO production could impact blood vessel function if such a mechanism is also present in PVAT. The affinity of NA for each receptor subtype should be considered when judging whether the presence of adrenoceptors on a particular cell type will produce a response. The multiple cell types in PVAT are instruments producing an adrenergic sonata that can be directed by NA's actions through adrenoceptors. What remains to be discovered are what mechanisms conduct this comprehensive orchestra in PVAT.
Innovative techniques to use when addressing questions on adrenergic mechanisms in PVAT
The current techniques used to investigate the biology of adipose tissue that could be applied to study the adrenergic system in PVAT include transplantation studies (Manka et al., 2014) , genetic tagging (Contreras et al., 2014) and optogenetics (Zeng et al., 2015) . Conditioned medium from PVAT applied to other cells and tissues can also be useful in studying the effects of PVAT-secreted factors on the SVF and vascular smooth muscle cells. Knockout models have also proved to be useful and will continue into the future. However, because the adrenergic system is essential for life and important in development, it can be challenging to interpret results from these models if an up-regulation of compensating mechanisms occurs. Conditional knock out models would allow for the probing of adrenergic mechanisms specific to adipocytes and specific cell types of the SVF. The challenge here would be to separate findings specific to PVAT from those due to other adipose tissue depots. A challenge in studying PVAT adipocyte biology is that primary adipocytes can only be cultured for a short time. Developments in protocols for culturing primary adipocytes such as ceiling culture, 3-dimensional culture and tissue explants expand the possibilities of PVAT experiments. Selective electroporation of adipocytes to introduce DNA is another useful technique, which is currently a part of the adipose researcher's tool box that could be used to investigate specific biochemical pathways of the adrenergic system (Granneman et al., 2004) . A limitation is that mature adipocytes are terminally differentiated and do not divide further. Thus, they cannot be passed in culture. However, preadipocytes can be and much of what we know about adipocyte biology has come from using primary preadipocytes, expanding and differentiating them into adipocytes in culture. Unfortunately, while there are several standard protocols for differentiation in the literature, these protocols are usually modified by each laboratory based on experimental needs and differences in differentiation response, which depend on the species and adipose depot. Thus, fair comparisons of findings between studies in these models are challenging to make.
At the centre of research on PVAT lies the question of what is considered PVAT. The most common adipose depots that are considered PVAT have been around the thoracic and abdominal aorta, mesenteric arteries and veins, carotid artery and femoral artery (Brown et al., 2014) . Additionally, other PVATs have been examined from skeletal muscle, saphenous vein and the renal sinus (Gil-Ortega et al., 2015) . What constitutes PVAT follows the common definition that PVAT is adipose tissue that surrounds arteries and veins. However, most blood vessels are surrounded by adipose tissue, yet only few representative PVATs have been examined. Studying physiological mechanisms in PVAT becomes complex as we do not have a general consensus as to what is considered PVAT. How far away does the adipose tissue have to be from the blood vessel to no longer be considered PVAT? For example, PVAT of the aorta is clearly separate from the surrounding tissue making removal straightforward and easily reproducible. However, PVAT within the skeletal muscle is without clear delineation. Furthermore, arteries and veins within the vascular network of adipose depots such as subcutaneous WAT and IBAT, for example, are surrounded by fat. However, this fat is generally not considered 'PVAT'. This is why it is crucial that great care be taken by researchers to describe the type of adipose tissue they use and any variables that may affect the experimental outcome to aid in interpretation of study results and allow for other laboratories to reproduce the protocols.
The adrenergic system in PVAT and its relevance in disease Attention on PVAT's influence on vascular function was precipitated by the need to understand the morbidity of obesity. Worldwide, 1.9 billion people are overweight, classified as having a body mass index (BMI) of ≥25 (World Health Organization, 2014). Moreover, 600 million adults are obese (BMI ≥ 30), a staggering number that represents 13% of the world population. People that are obese are at a higher risk of developing hypertension, metabolic syndrome and cardiovascular disease (World Health Organization, 2014) . There is substantial literature supporting increased SNS activity in obesity with hypertension (Hall et al., 2010; Kalil and Haynes, 2012) . Obesity-related hypertension responds better to treatment with α-adrenoceptor inhibitors than non-obesity-related hypertension, indicating adrenergic activity is an important factor in obesity-related hypertension (Wofford, 2001) . Studies have further implicated adipocytederived adipokines, such as leptin, as part of the mechanism responsible for the increase in sympathetic activity (Smith and Minson, 2012) . Adipocytes are enlarged in obesity and size-dependent changes in the adipocytes of obese individuals are associated with a dysregulation of adipokine secretion (Fernandez-Alfonso et al., 2013) and an increased release of angiotensin II, a stimulator of NA release (Cassis, 1993) . Increased visceral fat mass correlates with increased arterial pressure (Fox et al., 2007) . Changes in PVAT SVF resident cell populations occur in obesity (Nishimura et al., 2009) , and cells within the SVF can also contribute to the release of NA. Thus, this could be a mechanism by which NA at the site of α 1 -adrenoceptors on arteries is increased and causes contraction.
Antidepressants such as the 5-HT-NA reuptake inhibitor (SNRI) venlafaxine increase systolic blood pressure in patients with depression (Thase, 1998; Sir et al., 2005; Licht et al., 2009) . Another SNRI, sibutramine (used to treat obesity), had significant effects on blood pressure (Luque and Rey, 1999) . The inhibition of NA transporters in PVAT in response to SNRIs indicates another way that the adrenergic system in PVAT can have clinically relevant effects on blood pressure. However, the contribution of NA uptake inhibition in PVAT, or adipose tissue in general, leading to increased blood pressure needs to be investigated. This is an important research route as obese individuals are at a higher risk of developing high blood pressure than non-obese people (Kotchen, 2010) .
We have yet to understand why all overweight and obese people do not develop hypertension. Could a protective mechanism within PVAT exist that is dysfunctional in disease and differs in people? Clearly, we need to closely examine PVAT and the adrenergic components within it. In obesityassociated hypertension, a dysfunction of the normal anticontractile activities of PVAT is observed in addition to overall changes in adipocyte function (Aghamohammadzadeh and Heagerty, 2012) . Whether the PVAT dysfunction extends to its adrenergic system remains to be investigated. A local adrenergic system within PVAT could contribute to the increased SNS activity in obesity. Additionally, alterations in PVAT inflammatory status in obesity could have effects on the underlying blood vessels through catecholamine release from immune cells or the adipocytes. Increased metabolism of catecholamines by amine oxidases also has the potential to affect blood vessel function. Visentin et al. (2005) investigated the effects of a HFD on MAO and SSAO activity in WAT of obesity-prone and obesity-resistant mice. The authors reported increased MAO and SSAO activities in the WAT of obese mice compared with non-obese mice fed HFD. However, this increase in activity was due to an increase in the size of the adipose tissue depot, not the actual activity of the adipocytes (Visentin et al., 2005) . Interestingly, while adipocytes contain intracellular MAO-A and SSAO, they also shed a membrane bound form of SSAO into the circulation in a mechanism regulated by TNF-α and insulin (Abella et al., 2004) . Because SSAO can be shed from adipocytes, deamination of amines by SSAO may occur in the circulation at a distance away from the tissue depot from which it came. Metabolism of adrenoceptor agonists may reduce the amount the underlying vessels are exposed to, so decreasing vascular tone. The reaction catalysed by the amine oxidases releases H 2 O 2 and aldehydes as products, which could also affect vascular tone. H 2 O 2 can act as a vasodilator or vasoconstrictor depending on the vascular bed (Rubanyi, 1988) and can affect signalling in vascular smooth muscle, while the aldehydes have the ability to form advanced glycation end products and contribute to atherosclerosis (Vasdev et al., 2007) . MAO-A attenuates endothelium-dependent relaxation in the aorta through the production of H 2 O 2 , which limits endothelial NO formation (Sturza et al., 2013) . H 2 O 2 production through SSAO activity may also have this effect. Thus, the release of H 2 O 2 and aldehydes as products of amine metabolism could have multiple effects on vasomotor function.
Conclusion
PVAT makes up a neuro-immune-adipose 'triactome' that surrounds the vasculature (Chaldakov et al., 2014) . This makes PVAT an integral partner in the connection between obesity and hypertension. In both of these diseases, PVAT undergoes numerous changes that alter blood vessel function and their response to agonists (Galvez et al., 2006; Aghamohammadzadeh and Heagerty, 2012) . Factors that contribute to increases in blood pressure in hypertension include inflammation, endothelial dysfunction, atherosclerosis, adipokine secretion and the generation of reactive oxygen species, and these are, in some way, affected by obesity. As PVAT is an essential part of the blood vessel environment and provides a dynamic adrenergic system directly outside of most blood vessels, it should be included as a consideration in the elucidation of obesity-associated hypertension. What we need to know is whether the adrenergic system within PVAT is altered in obesity and whether this precipitates hypertension.
